Vienna Preserflo Cohort Study
Vienna Preserflo Microshunt Cohort Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Anticipated)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Clemens Vass, Univ.Prof
- Phone Number: 79400 0043140400
- Email: clemens.vass@meduniwien.ac.at
Study Locations
-
-
-
Vienna, Austria, 1090
- Recruiting
- Insitute of Ophthalmology and Optometry, Medical University of Vienna
-
Contact:
- Clemens Vass, Prof
- Phone Number: 40400 - 79400
- Email: clemens.vass@meduniwien.ac.at
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- Glaucoma patients who received a PMS in the time period between January and November 2019 at the Department of Ophthalmology, Medical University of Vienna, Austria, will be invited
Exclusion Criteria:
- Unwilling or unable to give informed consent.
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
IOP
Time Frame: one year
|
IOP in mmHg
|
one year
|
|
Full success
Time Frame: one year
|
IOP below 21 and IOP reduction of at least 20% from baseline without medication
|
one year
|
|
Qualified success
Time Frame: one year
|
IOP below 21 and IOP reduction of at least 20% from baseline with or without medication
|
one year
|
|
Complications
Time Frame: one year
|
Number of complications per eye
|
one year
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Re-intervention rate rate
Time Frame: one year
|
Proportion of eyes requiring either needling revision of filtering bleb revision or any other glaucoma surgery
|
one year
|
|
Medication rate
Time Frame: one year
|
Number of patients who needed again eye pressure lowering medication
|
one year
|
|
Average medication
Time Frame: one year
|
Average number of different eye pressure lowering medication
|
one year
|
|
OCT - shunt entry
Time Frame: one year
|
Shunt position in chamber angle as determined by anterior segment OCT
|
one year
|
|
OCT - shunt clearance
Time Frame: one year
|
Shunt-cornea angle as determined by anterior segment OCT
|
one year
|
|
OCT - shunt length
Time Frame: one year
|
Shunt length in the anterior chamber as determined by anterior segment OCT
|
one year
|
|
Corneal endothelial cell count
Time Frame: one year
|
Corneal endothelial cell count in specular microscopy of corneal endothelium
|
one year
|
Collaborators and Investigators
Sponsor
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Anticipated)
Primary Completion
Study Completion (Anticipated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 1142_2020
Drug and device information, study documents
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.